Breaking News
October 22, 2018 - Not exercising is worse than smoking, diabetes or heart disease finds study
October 22, 2018 - Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer
October 22, 2018 - Map of Mouse Hippocampus Could Be Weapon Against Alzheimer’s
October 22, 2018 - Psychotropic polypharmacy is common in Alzheimer’s disease
October 22, 2018 - Texas A&M and UTA establish Texas Genomics Core Alliance
October 22, 2018 - Analyzing mouse’s potential as animal model of decision-making
October 22, 2018 - Radiotherapy can prolong survival in prostate cancer
October 22, 2018 - A genetic mutation involved in relapse
October 21, 2018 - Report reveals growing impact of cannabis on young people
October 21, 2018 - NSF awards $5 million grant to help scientists magnify societal impact of research
October 21, 2018 - Fertility Rates Down for Each Urbanization Level 2007 to 2017
October 21, 2018 - Genetically engineered 3-D human muscle transplant in a murine model
October 21, 2018 - Moms’ tight work schedules may affect their children’s sleep
October 21, 2018 - AHA: No Direct Link Between Preeclampsia and Cognitive Impairment, Study Finds
October 21, 2018 - Weight loss success linked with active self-control regions of the brain
October 21, 2018 - Scripps researchers successfully test potential new smoking-cessation treatment in rodents
October 21, 2018 - More accurate and less stressful way to measure a baby’s heartbeat
October 21, 2018 - Researchers show better cardiorespiratory fitness leads to longer life
October 21, 2018 - Healthy candies for diabetic patients
October 21, 2018 - Environment impact of microplastics remains unclear
October 21, 2018 - Antibiotics for appendicitis? Surgery often not needed
October 21, 2018 - AHA and AMA recognize more than 800 medical practices, health systems for blood pressure control
October 21, 2018 - Scientists obtain clearest ever image of Ebola virus protein
October 21, 2018 - Study reveals connection between two proteins known to be hyperactive in cancer
October 21, 2018 - Gabapentin Beats Pregabalin for Chronic Sciatica
October 21, 2018 - Cosmetic surgeons offering incomplete information for breast augmentation customers
October 21, 2018 - Chronic sleep disruption in early adult life accelerates AD-related tau pathology
October 21, 2018 - Take 10 for Mindfulness – Drugs.com MedNews
October 21, 2018 - Length of breathing disruption in OSA may be better predictor of mortality risk
October 21, 2018 - ApoE4 gene linked with chronic inflammation increases risk for Alzheimer’s disease
October 21, 2018 - Mother-daughter conflict associated with suicide risk in abused adolescent girls
October 21, 2018 - Scientists molding bacteria into unnatural shapes
October 21, 2018 - High diet quality associated with lower risk of death in colorectal cancer patients
October 21, 2018 - Discharged mental health patients ‘at greater risk of dying’
October 21, 2018 - Research provides insight into neurobiology of aggression and bullying
October 21, 2018 - As billions in tax dollars flow to private Medicaid plans, Who’s minding the store?
October 21, 2018 - Neuroscientists identify brain region that appears to be related to food preference decisions
October 21, 2018 - Deaths related to air pollution in the U.S. decreased by 47% between 1990 and 2010
October 21, 2018 - Study shows correlation between spatial memory and the sense of smell
October 21, 2018 - Increased cardiorespiratory fitness associated with reduced long-term mortality
October 21, 2018 - IU researchers receive $1.55 million from NIH to improve chronic-disease management
October 21, 2018 - Income and wealth affect the mental health of Australians, study shows
October 21, 2018 - Patients with hypertension and psoriasis more often require cardiovascular interventions
October 20, 2018 - Leading hip-hop videos depict use of tobacco and marijuana products, study finds
October 20, 2018 - Dose Range of IV Ketamine for Adjunct Tx of Depression Tested
October 20, 2018 - Infants can distinguish between leaders and bullies, study finds
October 20, 2018 - Mad Cow disease found on Aberdeenshire farm
October 20, 2018 - Study identifies factors associated with prescription opioid misuse among students
October 20, 2018 - Scientists uncover key regulator of mTORC1 in cancer growth
October 20, 2018 - Pounds Regained After Weight-Loss Op Can Tell Your Doc a Lot
October 20, 2018 - Sending parents letters to fight childhood obesity doesn’t work
October 20, 2018 - Supervised aerobic exercise can support major depression treatment
October 20, 2018 - Mindfulness-based program effective for reducing stress in infertile women
October 20, 2018 - Molecule capable of halting and reverting neurodegeneration caused by Parkinson’s disease identified
October 20, 2018 - Midazolam-mediated alterations of PER2 expression may have functional consequences during myocardial ischemia
October 20, 2018 - Sweat bees are ideal for studying the genes underlying social behavior
October 20, 2018 - Weight loss success associated with brain areas involved in self-control
October 20, 2018 - KHN’s ‘What the Health?’ Republicans’ preexisting political problem
October 20, 2018 - Research provides a more complete picture of suffering caused by terrorist attacks
October 20, 2018 - Eradicating Helicobacter pylori infections may be a key treatment for Parkinson’s disease
October 20, 2018 - Breast Cancer as a Dynamic Disease
October 20, 2018 - University of Pittsburgh wins NSF grant for big data research to prevent complications from anesthesia
October 20, 2018 - Skin-to-skin contact may promote attachment between parents and preterm infants
October 20, 2018 - Recommendations Developed to Verify NGT Placement in Children
October 20, 2018 - Weight loss can be boosted fivefold thanks to novel mental imagery technique
October 20, 2018 - Children with autism are more likely to be overweight, obese
October 20, 2018 - Nurses making conscientious objections to ethically-relevant policies lack support
October 20, 2018 - Prion strain diversity may be greater than previously thought
October 20, 2018 - Antidepressant treatment may lead to improvements in sleep quality of patients with depression
October 20, 2018 - Study reports increased risk of death in children with inflammatory bowel disease
October 20, 2018 - Number of Autism Genes Now Tops 100
October 20, 2018 - Total diet replacement programmes are effective for treating obesity
October 20, 2018 - CLARIOstar used for fluorescence measurements on CSIRO’s purpose-built research vessel
October 20, 2018 - People with more copies of AMY1 gene digest starchy carbohydrates faster
October 20, 2018 - Case Comprehensive Cancer Center wins NIH grant to study health disparities
October 20, 2018 - Newly discovered compound shows potential for treating Parkinson’s disease
October 20, 2018 - High rate of non-adherence to hormonal therapy found among premenopausal early breast cancer patients
October 20, 2018 - Immunotherapy medicine found to be effective in treating uveitis
October 20, 2018 - The Pistoia Alliance Calls for Greater Collaboration to Realise Benefits of Innovation and Announces Winners of the 2018 President’s Startup Challenge
October 20, 2018 - Female internists consistently earn less than men
Two immunotherapy approaches for multiple myeloma show hope

Two immunotherapy approaches for multiple myeloma show hope

image_pdfDownload PDFimage_print

Researchers from the University of Pennsylvania’s Abramson Cancer Center have developed two experimental immunotherapy methods that include one chimeric antigen receptor (CAR) T cell therapy for the treatment of multiple myeloma patients who were not responding to other treatments.

Multiple myeloma is a cancer of the bone marrow. healthy plasma cells in the bone marrow mutate and multiply uncontrollably. malignant plasma cells produce a paraprotein. Image Credit: Designua / Shutterstock

Multiple myeloma is a cancer of the bone marrow. healthy plasma cells in the bone marrow mutate and multiply uncontrollably. malignant plasma cells produce a paraprotein. Image Credit: Designua / Shutterstock

The other study used a monoclonal antibody in treatment of multiple myeloma. Both of the studies would be presented as oral abstracts at the 59th Annual American Society of Hematology Meeting and Exposition in Atlanta.

The team of researchers administered CAR T cells to the multiple myeloma patients after they had undergone chemotherapy and found that 64 percent of the patients responded favorably after the therapy. In the other study an experimental monoclonal antibody was infused into patients with resistant multiple myeloma and an overall response rate of 60 percent was noted. According to the researchers that receptor targeted in both these immunotherapy approaches is called the B-Cell Maturation Antigen (BCMA). BCMA occurs in high abundance in patients with myeloma and thus can be used as a target for these drugs in multiple myeloma.

Multiple myeloma affects thousands of patients every year. According to the American Cancer Society the estimated number of new cases this year is around 30,200 and these patients are usually treated with chemotherapy, radiation therapy and stem cell transplant. Multiple myeloma affects particular immune cells called the plasma cells that become cancerous and multiply uncontrollably.

Study 1

The first study is presented as Abstract #505 which involves the use of CART-BCMA. Here the CAR T cells are developed specially by the researchers in collaboration with Novartis over the past five years. Patient’s own immune cells are collected and they are modified in such a manner so that they can find and destroy the cancer cells specifically. These are termed “hunter” cells that can target the BCMA receptor that is present over the cancer cells and can multiply within the body to kill the cancer cells. The normal white blood cells are suppressed first using a chemotherapy cycle before infusing these CAR-T cells. The patients included in the experimental clinical trial had all failed with traditional treatment before being enrolled for the study. On an average they had received some seven lines of therapy before this study and failed to respond adequately.

The group was divided into two dose groups of the CART-BCMA therapy – the lower dose included 5 patients and the higher dosage group had 10 patients. The lower dosage group showed minor response in at least 2 patients. Minor response was defined as 25 percent or more reduction in the levels of myeloma protein. In the higher dosage group, minor response was seen in eight patients (80 percent) and one patient showed complete response. The clinical trial is not yet concluded and more patients are being treated with the higher dose level. Of the 15 patients, side effects such as cytokine-release syndrome which manifests as flu like syndrome, nausea, fever, muscle pain etc. was noted in 12 patients. For this side effect one patient received tocilizumab and another received siltuximab as therapy. No deaths were seen during the study and three patients developed some nerve toxicity that did not persist. Study’s lead author Adam D. Cohen, assistant professor of Hematology and Oncology at Penn and the director of Myeloma Immunotherapy in Penn’s Abramson Cancer Center emphasized the importance of BCMA as an important target in treating multiple myeloma. The study was supported by the Penn-Novartis alliance.

Study 2

The second study presented as Abstract #741 used an experimental drug called GSK2857916. Dr. Cohen led this study as well. This new experimental drug was given breakthrough therapy designation by the US FDA this November so that it could be developed in an expedited fashion. This drug is combination of a chemotherapy drug called MMAF and a monoclonal antibody that targets the BCMA.

For the trial, 35 patients were given 16 treatment cycles with this experimental drug every three weeks. At the end of the study, 21 out of 35 (60 percent) showed some response to the drug. Around 51 percent showed a good partial response which meant that their myeloma protein levels reduced by over 90 percent. Media time that the patient spent without the disease progressing was around eight months.

Significant side effects in this study included eye toxicities such as dry eyes and blurry vision that was seen in 63 percent patients. Cohen added that there was a high response rate which had never been seen among these cases which were unresponsive to routine treatments.

Tagged with:

About author

Related Articles